HCV Indicator Denominators and Numerators for
AIDS Institute Funded HCV Care and Treatment Programs
Diagnosis of HCV Viremia
-Percentage of HCV Ab + patients who received an HCV RNA assay.
Denominator
-All patients with a HCV+ Ab test result during the
review period.
Numerator
-Number of patients who received an HCV RNA
test.
Exclusions: None
Alcohol Education-Part 1
-Percentage of HCV infected patients who were assessed for alcohol use.
Denominator
- All HCV RNA + patients during the review period.
Numerator
-Number of patients who received a standardized
assessment of alcohol use.
Exclusions: None
Alcohol Education-Part 2
-Percentage of HCV infected patients who were educated/counseled regarding alcohol use.
Denominator
-All HCV RNA+ patients during the review period
who reported a use of alcohol during the alcohol
use assessment.
Numerator
-Number of patients who received harm reduction
counseling regarding alcohol use.
Exclusions: None
HIV Screening
-Percentage of HCV infected patients who were screened and tested for HIV
Denominator
All HCV RNA + patients
Numerator
Number of patients screened and tested for
HIV
Exclusions: None
1
Substance Use Screening and Counseling
-Percentage of HCV infected patients who underwent substance use counseling.
Denominator
-All HCV RNA+ patients during the review period.
Numerator
-Number of patients who had a
discussion/assessment about substance use during
the review period with the following breakdown of
users:
i.
Current (within last 6 months)
ii.
Past (6 or more months)
iii.
Never (no history of SU)
Exclusions: None
Linkage to Care
-Percentage of HCV infected patients who were linked to HCV care.
Denominator
-All HCV RNA+ patients diagnosed during the
review period.
Numerator
- Number of HCV infected patients diagnosed
during the review period who were referred to an
experienced and trained HCV provider.(Refer to AI
definition of experienced and trained HCV
provider)
Exclusions: None
Adherence Assessment & Counseling-Barriers Discussion
-Percentage of HCV infected patients who had an assessment of the ability to successfully complete HCV
treatment and were counseled accordingly.
Denominator
-All HCV RNA+ patients
Numerator
-Number of patients who were assessed for
potential barriers to treatment adherence.
Exclusions: None
Fibrosis Staging
Percentage of HCV infected patients who were assessed for liver fibrosis.
Denominator
-All HCV RNA+ patients during the review period.
Numerator
-Number of HCV RNA+ patients who were
assessed for liver fibrosis.
Exclusions: None
HCV treatment Initiation
-Percentage of HCV infected patients who initiate HCV treatment
2
Denominator
- All HCV RNA+ patients.
Exclusions: None
Numerator
-Number of patients who initiate HCV treatment.
Genotype Testing Prior to Treatment
-Percentage of HCV infected patients who received a HCV Genotype Test prior to treatment initiation.
Denominator
-All HCV RNA+ patients who initiate treatment
during the review period.
Numerator
-Number of patients who received a genotype
test prior to HCV treatment initiation.
Exclusions: None
Adherence Assessment & Counseling-Education during Treatment
Percentage of HCV infected patients who received adherence assessment while on HCV therapy.
Denominator
-All HCV RNA+ patients initiating HCV treatment.
Numerator
-Number patients who received a quantitative
adherence assessment while receiving HCV
treatment.
Exclusions: None
Assessment of Sustained Virologic Response (SVR) after treatment completion.
-Percentage of HCV infected patients who have completed a full course of treatment and have
undetectable HCV RNA.
Denominator
-All HCV RNA+ patients who completed HCV
treatment.
Numerator
-Number patients who have an HCV RNA test at
least 12 weeks after treatment completion, but
no later than 30 weeks after the completion of
HCV treatment.
Exclusions: Patients currently on treatment or who completed treatment less 12 weeks from June
30, 2016 (the end of the data collection period).
3